What this pack is
EUTHYROX is the brand name in this record; levothyroxine sodium is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
EUTHYROXGeneric namelevothyroxine sodium
Mainland China pack-name cue优甲乐®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The U.S. public label describes levothyroxine sodium as synthetic T4. It helps explain the generic name, product identity and safety boundaries; it is not used to decide anyone's disease cause, laboratory target, tablet count, adjustment, switching or combination plan.
Read source: United States ↗reviewed 2026-08-23More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 优甲乐®
- International brand name
- EUTHYROX
- Source-scoped market brand names
- 优甲乐® · Mainland ChinaHistorical public record ↗The Merck China product page identifies EUTHYROX® as levothyroxine sodium tablets and describes a 2020 new-formulation launch and transition. It is only a name and formulation-history clue; it does not establish current approval, an exact strength/package, supply, sale eligibility or interchangeability with U.S. EUTHYROX, SYNTHROID or another levothyroxine product.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- levothyroxine sodium
- Dosage-form class
- Current U.S. public label: levothyroxine sodium oral tablets at 25, 50, 75, 88, 100, 112, 125, 137, 150, 175 and 200 mcg; this dossier precisely displays 50 mcg (0.05 mg), NDC 72305-050-30 and a 30-tablet blister-pack carton.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:优甲乐®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v10, effective 27 Jan 2026; prescribing information revised Dec 2025)
50 mcg (0.05 mg) per tablet; 30-tablet blister-pack carton (U.S. label)
- Product code
- NDC 72305-050-30
- Form and route
- levothyroxine sodium oral tablet · oral (label product-identity field)
- Container
- blister-pack carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- levothyroxine sodium
- 50 mcglabelled amount per tablet; not an individual's tablet count, adjustment or conversion instruction
- Package
- 30 tablets per carton
- Labelled appearance
- white · round tablet · imprint EM / 50
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
EUTHYROX / EUTHYROX China label reading: mcg, brand and market must be checked together
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the U.S. DailyMed EUTHYROX public label and the Merck China EUTHYROX name/formulation-history page to check exact product identity; it does not provide anyone's tablet count, interval, make-up use, adjustment, substitution, combination or stopping plan.
- 50 mcg equals 0.05 mg. This is a unit conversion for one tablet's identity, not an answer to daily tablet count, splitting or adjustment. Check the brand, generic name, labelled amount per tablet, form, package, target market and current prescription together.
- A shared levothyroxine ingredient, similar name or similar number does not make EUTHYROX, EUTHYROX China, SYNTHROID or another thyroid-hormone product self-substitutable, alternatable, combinable or convertible by tablet count. Labels and packages in different markets must be checked separately.
- The U.S. label includes language about food, calcium/iron-containing products, antacids and other medicine interactions. Actual timing or separation from another medicine must follow the current label for the exact product and individual advice from the prescribing team/pharmacist; this page does not generate a schedule.
- The U.S. label carries a boxed warning that it is not for weight loss or obesity treatment. With palpitations, chest pain, marked symptoms, a changed medicine list or an adverse-effect concern, contact local medical support; do not self-increase, make up, abruptly stop or change product from this page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-23
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. EUTHYROX levothyroxine sodium public label (Provell Pharmaceuticals; SPL v10, effective 27 Jan 2026) ↗reviewed 2026-08-23
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about EUTHYROX (levothyroxine sodium). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
EUTHYROX is the brand in this record and levothyroxine sodium is the active-ingredient name. Check both with the dosage form (Current U.S. public label: levothyroxine sodium oral tablets at 25, 50, 75, 88, 100, 112, 125, 137, 150, 175 and 200 mcg; this dossier precisely displays 50 mcg (0.05 mg), NDC 72305-050-30 and a 30-tablet blister-pack carton.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How levothyroxine sodium works: label pharmacology cannot replace an individual thyroid plan
- “Synthetic T4” is not a basis for self-diagnosis, interpreting laboratory results or changing a medicine independently. Symptoms and test results require interpretation by the prescribing team with the exact product, history and complete medicine list.
- A shared generic name or mechanism does not establish personal conversion or interchangeability between EUTHYROX, EUTHYROX China, SYNTHROID or another thyroid-related product; brand, strength, form, market and label version are all part of product identity.
- Do not use a mechanism page to manage acute chest pain, severe palpitations, fainting, marked breathing difficulty or another acute concern. With an acute or serious problem, prioritise local urgent medical support rather than experimenting with brand, strength or administration method.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. EUTHYROX levothyroxine sodium public label (Provell Pharmaceuticals; SPL v10, effective 27 Jan 2026) ↗reviewed 2026-08-23
- Merck China: EUTHYROX® levothyroxine sodium tablet page (2020 China new-formulation launch history) ↗Historical public record · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
EUTHYROXlevothyroxine sodium
This page includes an exact current U.S. public-label package panel for EUTHYROX, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the public label
The U.S. DailyMed public label for EUTHYROX lists Initial U.S. Approval: 2002. This year only locates this U.S. label history; it does not establish approval, supply, sale eligibility, originator/generic relationship, interchangeability or individual suitability in Mainland China or another market.
DailyMed (NLM): current U.S. EUTHYROX levothyroxine sodium public label (Provell Pharmaceuticals; SPL v10, effective 27 Jan 2026) ↗EUTHYROX China new-formulation launch history
The Merck China page identifies EUTHYROX® as levothyroxine sodium tablets and describes a late-March 2020 China new-formulation launch. It is used only to check the name and formulation-transition context, not current approval, exact packaging, supply, sale eligibility or interchangeability with U.S. EUTHYROX, SYNTHROID or another product.
Merck China: EUTHYROX® levothyroxine sodium tablet page (2020 China new-formulation launch history) ↗Current U.S. DailyMed public label effective
This dossier uses DailyMed SPL v10 (effective 27 Jan 2026; prescribing information revised Dec 2025) to check U.S. EUTHYROX 50 mcg, NDC 72305-050-30 and the 30-tablet blister-pack carton. It does not establish actual marketing, stock, purchase, individual tablet count, adjustment or switching.
DailyMed (NLM): current U.S. EUTHYROX levothyroxine sodium public label (Provell Pharmaceuticals; SPL v10, effective 27 Jan 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current public label and one exact carton panel linkedThis page displays only EUTHYROX levothyroxine sodium 50 mcg (0.05 mg), NDC 72305-050-30 and a 30-tablet blister-pack carton. It does not authenticate a product or establish actual marketing, stock, purchase, individual tablet count, timing, adjustment, switching or interchangeability.
Mainland China
Brand-name and formulation-history clue linked; current market record not establishedThe Merck China page can be used to check the EUTHYROX® / levothyroxine sodium tablet name and its 2020 formulation-transition context. No current China approval, package, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from that page, the U.S. label, NDC, English brand or package image.
Other markets
Market record not establishedNo trade name, approval, strength, supply, sale eligibility or interchangeability in another market is inferred from the U.S. or China material; every market needs separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 优甲乐®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Are 50 mcg and 0.05 mg two different strengths?
They are unit expressions of the same labelled amount per tablet. This only helps check package identity; it does not answer tablet count, splitting, adjustment or whether another product can be substituted.
Can EUTHYROX China and U.S. EUTHYROX be directly exchanged by name or mcg?
No. The public materials are from different markets: the U.S. page is a current U.S. label, while the China page is a name/formulation-history clue. A shared brand, generic name or similar number does not create personal conversion or interchangeability; have a pharmacist or prescribing team check the actual pack, current target-market label and full medicine list.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.